Takeda Pharmaceutical
308 hedge funds and large institutions have $1.06B invested in Takeda Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 113 increasing their positions, 92 reducing their positions, and 36 closing their positions.
3,914% more call options, than puts
Call options by funds: $25.9M | Put options by funds: $646K
47% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 36
23% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 92
11% more capital invested
Capital invested by funds: $954M → $1.06B (+$104M)
3% more funds holding
Funds holding: 300 → 308 (+8)
0.06% less ownership
Funds ownership: 4.53% → 4.47% (-0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$48.1M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$11.8M |
| 3 |
Goldman Sachs
New York
|
+$9.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.71M |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$6.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$39.5M |
| 2 |
Millennium Management
New York
|
-$24.6M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$15.6M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.01M |
| 5 |
CCM
Causeway Capital Management
Los Angeles,
California
|
-$6.91M |
TAK Hedge Fund Activity: Q1 2025 in Review
308 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2025, worth a combined $1.06B — up 11% from $954M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new TAK positions and 36 closed out — a net gain of 17 holders — while 113 added to existing stakes and 92 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $48.1M. The largest seller was Arrowstreet Capital, cutting an estimated $39.5M.
- 308 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2025, up from 300 in Q4 2024.
- Funds reported $1.06B of Takeda Pharmaceutical stock for Q1 2025, up 11% quarter-over-quarter.
- 53 funds opened new Takeda Pharmaceutical positions in Q1 2025 and 36 closed out, a net change of +17 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2025 was Adage Capital Partners, an estimated $48.1M added.
- The largest Takeda Pharmaceutical seller in Q1 2025 was Arrowstreet Capital, an estimated $39.5M sold.
Based on aggregated 13F filings for Q1 2025.